Compare PLUG & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLUG | MYGN |
|---|---|---|
| Founded | 1997 | 1991 |
| Country | United States | United States |
| Employees | N/A | 2700 |
| Industry | Industrial Machinery/Components | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 444.2M |
| IPO Year | 1999 | 1996 |
| Metric | PLUG | MYGN |
|---|---|---|
| Price | $2.44 | $4.75 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 8 |
| Target Price | $2.12 | ★ $7.64 |
| AVG Volume (30 Days) | ★ 60.2M | 1.6M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.01 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $709,919,000.00 | ★ $771,400,000.00 |
| Revenue This Year | $15.60 | $6.89 |
| Revenue Next Year | $18.77 | $5.35 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.90 | 2.33 |
| 52 Week Low | $0.69 | $3.76 |
| 52 Week High | $4.58 | $8.63 |
| Indicator | PLUG | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 59.84 | 50.25 |
| Support Level | $1.43 | $4.24 |
| Resistance Level | $2.49 | $5.69 |
| Average True Range (ATR) | 0.15 | 0.30 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 88.24 | 64.71 |
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.